Skin Care Research

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Vitiligo3 trials
• Atopic dermatitis (eczema)2 trials
• Obesity2 trials
• Psoriasis2 trials

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 41 trial

Status

• Completed3 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Pfizer2 trials
• Acrotech Biopharma Inc.1 trial
• Apollo Therapeutics Ltd1 trial
• Vyne Therapeutics Inc.1 trial

Running trials

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source

  Contact: Kimberly Gardner

• Recruiting

  A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  NCT06857942· Phase 4· Eli Lilly and Company· Source

  Contact: Eduardo Weiss (principal investigator)

• Active, not recruiting

  A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

  NCT06163326· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Obesity1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

  NCT06588283· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

  NCT06493578· Phase 2· Vyne Therapeutics Inc.· Source

• Completed

  A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

  NCT05583526· Phase 3· Pfizer· Source

• Completed

  A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

  NCT05571943· Phase 3· Acrotech Biopharma Inc.· Source